You are here: Home > Institute of Excellence (CPD) > Calendar > CPD Events > Emerging Anti-VEGF therapies and New Vitreoretinal Disease Treatments

Emerging Anti-VEGF therapies and New Vitreoretinal Disease Treatments

Date: 20/03/2019

Venue: 7 Lakeside Boulevard, Pakenham, VIC, 3072

Provider: Dr Jonathan Yeoh

Contact: Jonathan Yeoh, [E] referral@retina-doctors.net, [P] (03) 96623808

Learning Objectives

  • At the completion of the course participants should have an understanding of new and emerging anti-VEGF therapies in the treatment of neovascular age related macular degeneration, diabetic macular oedema and retinal vein occlusion
  • The participants should be able to understand of the management of subluxed lenses with intrascleral haptic intraocular lens fixation. Also they will have gained insight into the management of large macular holes with internal limiting membrane flaps and the use of plasminogen activator injections to displace submacular haemorrhage
  • At the completion of the course participants will have learnt about the artificial retina prosthesis, advances in gene therapy and stem cell therapy.

Max points awarded: 4.00

Session Information

Name
Emerging Anti-VEGF therapies
Activity Type
Face to Face with Assessment
Therapeutic?
No
Manufacturer/Supplier?
No
Points for attending & Passing Assessment
1.50
Name
Management of subluxed lenses by new haptic intraocular lens fixation technique
Activity Type
Face to Face with Assessment
Therapeutic?
No
Manufacturer/Supplier?
No
Points for attending & Passing Assessment
1.00
Name
New treatments in Vitreoretinal disease
Activity Type
Face to Face with Assessment
Therapeutic?
No
Manufacturer/Supplier?
No
Points for attending & Passing Assessment
1.50

NameActivity TypeTherapeutic?Manufacturer/
Supplier?
Points for attending &
Passing Assessment
Emerging Anti-VEGF therapiesFace to Face with AssessmentNoNo1.50
Management of subluxed lenses by new haptic intraocular lens fixation techniqueFace to Face with AssessmentNoNo1.00
New treatments in Vitreoretinal diseaseFace to Face with AssessmentNoNo1.50